Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 5004 Neoplasms 4197 Prostatic Neoplasms 2428 Carcinoma, Non-Small-Cell Lung 2265 Colorectal Neoplasms 2053 Lung Neoplasms 1705 Multiple Myeloma 1459 Lymphoma 1405 Leukemia, Myeloid, Acute 1382 Neoplasm Metastasis 1374 Melanoma 1270 Pancreatic Neoplasms 1200 Leukemia 1196 Ovarian Neoplasms 1192 Lymphoma, Non-Hodgkin 1132 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1091 Head and Neck Neoplasms 1056 Leukemia, Lymphocytic, Chronic, B-Cell 994 Lymphoma, Follicular 897 Colonic Neoplasms 895 Brain Neoplasms 876 Stomach Neoplasms 857 Recurrence 853 Carcinoma, Hepatocellular 846 Glioblastoma 841 Lymphoma, Large B-Cell, Diffuse 771 Rectal Neoplasms 759 Uterine Cervical Neoplasms 728 Carcinoma, Renal Cell 705 Hodgkin Disease 698

Interventions

sodium calcium aluminosilicate, hydrated 1 Calcium Carbonate 1 ACCS100 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Interventional × Aflatoxin Poisoning × Clear all

NCT01677195 2016-04-19

RDMEACCS100

Texas Enterosorbents Incorporated

Phase 2 Completed

234 enrolled 7 charts

Aflatoxin Poisoning, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡